Maghreb Private Equity Fund

Maghreb Private Equity Fund is one of the legacy vehicles managed by AfricInvest, the Tunis-based firm that has been investing across North and Sub-Saharan Africa for more than two decades. This is not a venture fund in any meaningful sense. It is a control-and-influence private equity vehicle that writes $5M to $25M checks at Series B and growth stages into established mid-cap businesses across Tunisia, Morocco, Algeria, and Egypt. Within healthcare, its remit is healthcare infrastructure and tech-enabled care delivery: hospital groups, diagnostic chains, pharmacy networks, and operating businesses with real assets, real revenue, and real EBITDA. Founders building software-only digital health products are not the audience here. Operators consolidating clinics across the Maghreb, building regional diagnostic platforms, or scaling specialty care chains absolutely are. The regional advantage is genuine. AfricInvest has on-the-ground relationships with regulators, family offices, and operating partners across North Africa that very few firms can match, and the operational support extends to governance upgrades, ESG integration, regional expansion playbooks, and exit preparation through trade sales or local listings. The right founder profile is a CEO who is already running a profitable or near-profitable healthcare operating business, who is open to a meaningful equity stake going to a financial partner with board influence, and who needs capital paired with institutional discipline to execute an acquisition-led regional strategy. The wrong profile is an early-stage AI startup; AfricInvest is not where pre-revenue technology bets live. The right entry path is through the AfricInvest team in Tunis, Casablanca, or Cairo, ideally introduced by a regional advisor, banker, or a portfolio CEO. Cold inbound is unlikely to land. When pitching, lead with audited financials, a defensible market position, and a thesis on how additional capital plus governance support unlocks regional scale. Articulate the exit thesis early, because PE funds underwrite to a defined holding period and a credible buyer universe. Caveats include the standard PE realities: significant control rights, a hands-on board, and an expectation that the company will professionalize quickly under their stewardship. Founders who want to remain captain of an early-stage venture-style company should not pitch this fund; founders ready to run a regional healthcare platform with institutional backing will find few better partners in the Maghreb.